Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Jul 2017;262:51-54
Nonalcoholic steatohepatitis is the most common cause of chronic liver disease in the western countries (up to 24% of all patients with liver disease), with 75% of those with NASH being classified as obese (1)
This leads to a very hot question in the field right now: rebound effect
KEY OBSERVATIONS The website crosses out $247 and shows $175 as the price, but $175 requires a six-month commitment
Crucially, the fund provides exposure not only to large companies involved in producing or selling GLP-1 therapeutics, but also to those creating other weight loss enablers and even to companies supporting the supply chain vital to production
Study Rationale SURMOUNT-1 Trial Historically, the treatment of obesity focused almost exclusively on lifestyle-based approaches
US$ 29.85
US$ 20.81
US$ 27.63
US$ 25.26
US$ 21.61
US$ 23.70
US$ 22.78
&srotate=0)
US$ 29.82
US$ 26.41
US$ 24.07
US$ 25.37
